> 課題検索詳細
前に戻る
検索画面に戻る
研究課題情報
(単位:千円)
研究成果情報
1.間石奈湖, 樋田京子: 腫瘍血管内皮細胞における異常性解明とその制御,高倉伸幸編「細胞」-特集 がんの進展における血管新生と免疫-,ニューサイエンス社,53(2),49-52,2021
2.樋田京子, 間石奈湖: 血管内皮増殖因子, 「産科と婦人科 特集 分子標的薬を極める―基礎から臨床まで―」, 診断と治療社, 87(10), 1145-1149, 2020
3.間石奈湖, Annan DA, 樋田京子: 「がん治療標的としての腫瘍血管内皮細胞の特異性」, 『炎症と免疫』, 先端医学社, 28(5), 35-40, 2020
4.西原広史 5.がんゲノム医療から広がる臨床研究 特集/がんゲノム医療の新展開 月刊『腫瘍内科』第25巻第1号 2020年1月発行
5.中村康平、西原広史 ゲノム医療の展望 臨牀と研究 97(4)391-397, 2020
6.Annan DA, Kikuchi H, Maishi N, Hida Y and Hida K*: Tumor Endothelial Cell-A Biological Tool for Translational Cancer Research, Int. J. Mol. Sci., 21, 3238, 2020 doi: 10.3390/ijms21093238
7.Li C, Maishi N, Annan DA, Young MF, Morimoto H, Morimoto M, Nam JM, Hida Y, Hida K: Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy, Breast Cancer Res, in press
8.Yanagiya M, Dawood RIH, Maishi N, Hida Y, Torii C, Annan DA, Kikuchi H, Yanagawa Matsuda A, Kitamura T, Tei K, Shindoh M, Tanaka S, Kitagawa Y, Hida K: Correlation between endothelial chemokine receptor 7CXCR7 expression and clinicopathological factors in oral squamous cell carcinoma, Pathol Int, 2021 doi: 10.1111/pin.13094
9.Morimoto H, Hida Y, Maishi N, Nishihara H, Hatanaka Y, Li C, Matsuno Y, Nakamura T, Hirano S, Hida K: Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer, Thorac Cancer, 2021 doi:10.1111/1759-7714.1390
10.Hiradate R, Khalil IA, Matsuda A, Sasaki M, Hida K, Harashima H: A novel dual-targeted rosiglitazone-loaded nanoparticle for the prevention of diet-induced obesity via the browning of white adipose tissue, J Controlled Release, 329(10), 665-675, 2020 doi: 10.1016/j.jconrel.2020.10.002
11.Kikuchi H, Maishi N, Annan DA, Alam MT, Dawood RIH, Sato M, Morimoto M, Takeda R, Ishizuka K, Matsumoto R, Akino T, Tsuchiya K, Abe T, Osawa T, Miyajima N, Maruyama S, Harabayashi T, Azuma M, Yamashiro K, Ameda K, Kashiwagi A, Matsuno Y, Hida Y, Shinohara N and Hida K*: Chemotherapy-induced IL-8 upregulates MDR1/ABCB1 in tumor blood vessels and results in unfavorable outcome, Cancer Res, 80(14), 2996-3008, 2020 doi:10.1158/0008-5472.CAN-19-3791
12.Yoshimatsu Y, Wakabayashi I, Kimuro, S, Takahashi N, Takahashi K, Kobayashi, M, Maishi N, Inoue K, Hida K, Miyazono K, Watabe T: TNF-α enhances TGF-β-induced endothelial-to-mesenchymal transition via TGF-β signal augmentation, Cancer Sci, 111(7), 2385-2399, 2020 doi: 10.1111/cas.14455
13.Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma: Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N; Japanese Urological Oncology Group, Cancer Sci. 2020;111(7):2460-2471 doi: 10.1111/cas.14449
14.The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer: Miyata H, Osawa T, Abe T, Kikuchi H, Matsumoto R, Maruyama S, Nishioka K, Shimizu S, Hashimoto T, Shirato H, Shinohara N, Japanese journal of clinical oncology. 2020;50(5):609-16. doi: 10.1093/jjco/hyz211
15.Oncologic outcomes of laparoscopic radical nephroureterectomy in conjunction with template-based lymph node dissection: An extended follow-up study: Matsumoto R, Abe T, Takada N, Minami K, Harabayashi T, Nagamori S, Hatanaka KC, Yamashiro K, Kikuchi H, Osawa T, Maruyama S, Shinohara N, Urologic oncology. 2020. doi: 10.1016/j.urolonc.2020.05.013
16.Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy: Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, Miyata H, Frumido J, Matsumoto R, Osawa T, Junji I, Tango M, Satoshi C, Tomoshige A, Masashi M, Naoto M, Kunihiko T, Satoru M, Murai S, Shinohara N, Japanese journal of clinical oncology. 2020;50(2):206-13. doi: 10.1093/jjco/hyz152
17.Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system: Hayashi H, Tanishima S, Fujii K, Mori R, Okada C, Yanagita E, Shibata Y, Matsuoka R, Amano T, Yamada T, Yabe I, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H, Cancer Sci. 2020 Aug 8. doi: 10.1111/cas.14608
18.Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met. Uemura, S., Wang, L., Tsuda, M., Suzuka, J., Tanikawa, S., Sugino, H., Nakamura, T., Mitsuhashi, T., Hirano, S., Tanaka, S.Biochem Biophys Res Commun 2020, 524, 378-384. 10.1016/j.bbrc.2020.01.105
19.MM2 cortical form of sporadic Creutzfeldt-Jakob disease without progressive dementia and akinetic mutism: A case deviating from current diagnostic criteria Takahashi-Iwata, I., Yabe, I., Kudo, A., Eguchi, K., Wakita, M., Shirai, S., Matsushima, M., Toyoshima, T., Chiba, S., Tanikawa, S., Tanaka, S., Satoh, K., Kitamoto, T., Sasaki, H.J Neurol Sci 2020, 15, 116759. 10.1016/j.jns.2020.116759
20.Cisplatin Relocalizes RNA Binding Protein HuR and Enhances the Oncolytic Activity of E4orf6 Deleted Adenovirus. Habiba, U., Hossain, E., Yanagawa-Matsuda, A., Chowdhury, AFMA., Tsuda, M., Zaman, A., Tanaka, S., Higashino, F.Cancers (Basel), 2020, 12, 809. 10.3390/cancers12040809
1.樋田京子:Oncology インターネット講演会, "腫瘍血管内皮細胞の特性とがん免疫", 2021.3.29(札幌), 口頭, シンポジウム・招待講演
不明 / 講演
2.樋田京子:第94回日本薬理学会年会シンポジウム「血管内皮細胞研究の最前線と創薬」, "The Role of tumor endothelial cells in cancer progression(腫瘍血管内皮細胞とがんの悪性化)", 2021.3.10(WEB開催), 口頭, シンポジウム・招待講演
3.樋田京子:令和2年度 弘前大学第1回生体応答科学研究セミナー, "腫瘍血管内皮細胞の異常性とがんの悪性化", 2020.11.25(WEB開催), 口頭, シンポジウム・招待講演
4.樋田京子:Breast Cancer Investigator’s Meeting in Sapporo, "腫瘍血管と免疫小環境", 2020.11.18(札幌), 口頭, シンポジウム・招待講演
5.間石奈湖, 菊地 央, 樋田 泰浩, 篠原信雄, 樋田京子: 抗癌剤治療がもたらす腫瘍血管トランスポーター発現亢進とその機序, 依頼講演, 第6回北海道大学部局横断シンポジウム"若手研究者による生命と物質の融合を目指して!", 2020.10.19(WEB開催), 口頭, シンポジウム・招待講演
6.樋田京子: 第24回日本がん免疫学会総会シンポジウム2「腫瘍微小環境とその制御」,"腫瘍血管内皮細胞の特性とがん免疫", 2020.10.9(札幌), 口頭, シンポジウム・招待講演
7.Hida K: The 79th Annual Meeting of the Japanese Cancer Assosiation Symposium, Real world of tumor microenvironment, "The role of tumor endothelial cells in the immune environment", 2020.10.2, Hiroshima, Japan, Oral, シンポジウム・招待講演
8.樋田京子: 第79回日本癌学会学術総会特別シンポジウム「がん研究における女性研究者(WSCR)Women scientists in cancer research」, "治療標的としての腫瘍血管内皮細胞の異常性", 2020.10.1(広島), 口頭, シンポジウム・招待講演
9.Hida K: New Insights Into Drug-Resistance: Abnormality in Tumor Endothelial Cells, The 21th International Vascular Biology Meeting, 2020.9.11, Seoul, Korea, Oral, シンポジウム・招待講演
10.樋田京子:第109回日本病理学会総会シンポジウム「口腔腫瘍の病理と遺伝子異常―がん形質と微小環境」"腫瘍血管内皮細胞の特性解析とがん治療への応用"2020. 4.18(福岡), 口頭, シンポジウム・招待講演
11.Shinya Tanaka Investigation System of Medical Accident in Japan,口頭(講演), 第109回日本病理学会総会オンライン総会 2020/7/1-31, 国内, シンポジウム・招待講演
国内 / 講演
12.Maishi N, Sakurai Y, Hatakeyama H, Li C, Alam MT, Kikuchi H, Morimoto H, Morimoto M, Akiyama K, Ohga N, Hida Y, Harashima H, Hida K: Novel Antiangiogenic Therapy Targeting Biglycan in Tumor Endothelial Cell Using Liposomal-siRNA Delivery System, E-poster, The 21st International Vascular Biology Meeting (IVBM 2020), 2020.9.9-12, Seoul, Korea
不明 / ポスター
13.Annan DA, Maishi N, Soga T, Dawood RIH, Li C, Kikuchi H, Hojo T, Morimoto M, Kitamura T, Alam MT, Minowa K, Shinohara N, Nam JM, Hida Y, Hida K: Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment E-poster, The 21st International Vascular Biology Meeting (IVBM 2020), 2020.9.19-12 Seoul, Korea
14.Li C, Maishi N, Annan DA, Hida Y, Hida K: Biglycan deficiency normalizes tumor blood vessels and potentiates tumor immune responses, E-poster, The 21st International Vascular Biology Meeting (IVBM 2020), 2020.9.9-12, Seoul, Korea
15.Tsumita T, Annan DA, Maishi N, Hida Y, Hida K: The role of LOX-1 in tumor endothelial cells on tumor metastasis, E-poster, The 21st International Vascular Biology Meeting (IVBM 2020), 2020.9.9-12, Seoul, Korea
16.Kikuchi H, Maishi N, Dorcas A. Annan, Alam TM, Matsumoto R, Osawa T, Abe T, Hida Y, Harabayashi T, Ameda K, Kashiwagi A, Matsuno Y, Shinohara N, Hida K: Increased ABCB1 expression in tumor blood vessels of urothelial carcinoma after chemotherapy and chemoresistance, E-poster, The 21st International Vascular Biology Meeting (IVBM 2020), 2020.9.9-12, Seoul, Korea
17.間石 奈湖,梅山 悠伊,菊地 央,古御堂 純,佐藤 峰嘉,武田 遼,Dorcas A. Annan, 篠原 信雄,樋田 泰浩,樋田 京子:Crosstalk of tumor cells and tumor endothelial cells by forming cell clusters promotes tumor metastasis, 第28回日本血管生物医学会学術集会, 2021.3.12(WEB開催)
不明 /
18.Li C, 間石奈湖, Annan DA, 樋田泰浩, 樋田京子: Title in English: Inhibition of stromal biglycan normalizes tumor microenvironment and enhances chemotherapeutic efficacy, 第28回日本血管生物医学会学術集会, 2021.3.12(WEB開催)
19.新山 宗, 間石奈湖, 松田 彩, 樋田泰浩, 鄭 漢忠, 上田倫弘, 樋田京子: Association between high endothelial venules and clinical factors in oral squamous cell carcinoma, 第28回日本血管生物医学会学術集会, 2021.3.12(WEB開催)
20.積田卓也, Annan DA, 間石奈湖, 樋田泰浩, 樋田京子: The role of LOX-1 in tumor endothelial cells on tumor metastasis, 第28回日本血管生物医学会学術集会, 2021.3.12(WEB開催)
更新日:2022-05-11